- Home
- PMN vs INKT Comparison
PMN vs INKT Comparison
Compare PMN & INKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PMN
- INKT
- Stock Information
- Founded
- PMN 2004
- INKT 2017
- Country
- PMN Canada
- INKT United States
- Employees
- PMN N/A
- INKT N/A
- Industry
- PMN Pharmaceuticals and Biotechnology
- INKT Medicinal Chemicals and Botanical Products
- Sector
- PMN Health Care
- INKT Health Care
- Exchange
- PMN Nasdaq
- INKT Nasdaq
- Market Cap
- PMN 32.3M
- INKT 28.5M
- IPO Year
- PMN N/A
- INKT 2021
- Fundamental
- Price
- PMN $0.92
- INKT $0.50
- Analyst Decision
- PMN
- INKT Strong Buy
- Analyst Count
- PMN 0
- INKT 2
- Target Price
- PMN N/A
- INKT $6.50
- AVG Volume (30 Days)
- PMN 80.8K
- INKT 53.3K
- Earning Date
- PMN 12-31-2024
- INKT 11-14-2024
- Dividend Yield
- PMN N/A
- INKT N/A
- EPS Growth
- PMN N/A
- INKT N/A
- EPS
- PMN N/A
- INKT N/A
- Revenue
- PMN N/A
- INKT N/A
- Revenue This Year
- PMN N/A
- INKT N/A
- Revenue Next Year
- PMN N/A
- INKT N/A
- P/E Ratio
- PMN N/A
- INKT N/A
- Revenue Growth
- PMN N/A
- INKT N/A
- 52 Week Low
- PMN $0.87
- INKT $0.46
- 52 Week High
- PMN $3.10
- INKT $1.90
- Technical
- Relative Strength Index (RSI)
- PMN 45.09
- INKT 31.23
- Support Level
- PMN $0.87
- INKT $0.46
- Resistance Level
- PMN $0.94
- INKT $0.67
- Average True Range (ATR)
- PMN 0.07
- INKT 0.06
- MACD
- PMN -0.00
- INKT -0.02
- Stochastic Oscillator
- PMN 31.31
- INKT 22.13
About PMN ProMIS Neurosciences Inc. (ON)
ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine is based on the use of two complementary techniques. The company applies its thermodynamic, computational discovery platform-ProMIS and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins.
About INKT MiNK Therapeutics Inc.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing allogeneic invariant natural killer T-cell therapies to treat cancer and other life-threatening illnesses.